Latham & Watkins Advises the Underwriters in Mirum Pharmaceuticals’ Public Offering

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, has announced the pricing of its previously announced underwritten public offering of 3,478,261 shares of its common stock at a price to the public of US$23 per share. The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be US$80 million.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by Bay Area partner Brian Cuneo, with Orange County associates Eric Hanzich and AJ Blair. Advice was also provided on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Washington, D.C. associate Chad Jennings; on intellectual property matters by Bay Area/San Diego partner Chris Hazuka, with San Diego associates Robert Yeh and Kristina Funahashi; and on tax matters by Bay Area partner Grace Lee, with Washington, D.C. associate Eni Kassim.